Serial 2-[18F] fluoro -2 -deoxy -D -glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
The response of bone-dominant (BD) breast cancer to therapy is difficult to assess by conventional imaging. Our preliminary studies have shown that quantitative serial 2-[(18)F] fluoro-2-deoxy-D: -glucose positron emission tomography (FDG PET) correlates with therapeutic response of BD breast cancer...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2007-09, Vol.105 (1), p.87-94 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 94 |
|---|---|
| container_issue | 1 |
| container_start_page | 87 |
| container_title | Breast cancer research and treatment |
| container_volume | 105 |
| creator | SPECHT, Jennifer M TAM, Stephen L KURLAND, Brenda F GRALOW, Julie R LIVINGSTON, Robert B LINDEN, Hannah M ELLIS, Georgiana K SCHUBERT, Erin K DUNNWALD, Lisa K MANKOFF, David A |
| description | The response of bone-dominant (BD) breast cancer to therapy is difficult to assess by conventional imaging. Our preliminary studies have shown that quantitative serial 2-[(18)F] fluoro-2-deoxy-D: -glucose positron emission tomography (FDG PET) correlates with therapeutic response of BD breast cancer, but the relationship to long-term outcome measures is unknown. Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment.
We reviewed medical records of 405 consecutive breast cancer patients referred for FDG PET. Of these, 28 demonstrated metastatic BD breast cancer, were undergoing treatment, had at least 2 serial PET scans, and had abnormal FDG uptake on the first scan. Standardized uptake value (SUV) for the most conspicuous bone lesion at the initial scan, absolute change in SUV over an interval of 1-17 months, and percent change in SUV were considered as predictors of time-to-progression (TTP) and time to skeletal-related event (t-SRE).
Using proportional hazards regression, smaller percentage decreases in SUV (or increases in SUV) were associated with a shorter TTP (P < 0.006). A patient with no change in SUV was twice as likely to progress compared to a patient with a 42% median decrease in SUV. A higher SUV on the initial FDG PET predicted a shorter t-SRE (hazard ratio = 1.30, P < 0.02).
Changes in serial FDG PET may predict TTP in BD metastatic breast cancer patients. However, larger prospective trials are needed to validate changes in FDG PET as a surrogate endpoint for treatment response. |
| doi_str_mv | 10.1007/s10549-006-9435-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68163981</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1323079721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-adb2d652fbe07c94dc811066deec109b8c43fe242f960d6a47e0ae1eb17a2c403</originalsourceid><addsrcrecordid>eNqFktFqFDEUhgdR7Fp9AG8kCEp7ET3JZJLJpbTdKhQsuF6JhEzmTE2ZmaxJBtz38gHNugsFb7xKOHz5T06-VNVLBu8YgHqfGDRCUwBJtagbyh5VK9aomirO1ONqBUwqKluQJ9WzlO4BQCvQT6sTprhsW6ZX1e8vGL0dCaffWLv-ToZxCTEQygntMfzaEXpJ6N24uJCQbEPyOYaZ4ORT8mWTwxTuot3-2JGz9eU1vb3anJcimcLsc4gkR7R5wjmTMJAuzEj7MPnZlsKE2aZss3ekK1TKxNnZYSTbiL13OZHsJ9yHbWPpgYeGZ5vN7fnz6slgx4Qvjutp9XV9tbn4SG8-X3-6-HBDnWjqTG3f8V42fOgQlNOidy1jIGWP6BjornWiHpALPmgJvbRCIVhk2DFluRNQn1ZvD7nlBj8XTNmUuR2Oo50xLMnIlslat-y_IAeumuYv-Pof8D4scS5DGM64aJRoeYHYAXIxpBRxMNvoJxt3hoHZizcH8aaIN3vxZh_86hi8dBP2DyeOpgvw5gjY5Ow4xPLYPj1wGriG8nf-AD65tpg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212457482</pqid></control><display><type>article</type><title>Serial 2-[18F] fluoro -2 -deoxy -D -glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>SPECHT, Jennifer M ; TAM, Stephen L ; KURLAND, Brenda F ; GRALOW, Julie R ; LIVINGSTON, Robert B ; LINDEN, Hannah M ; ELLIS, Georgiana K ; SCHUBERT, Erin K ; DUNNWALD, Lisa K ; MANKOFF, David A</creator><creatorcontrib>SPECHT, Jennifer M ; TAM, Stephen L ; KURLAND, Brenda F ; GRALOW, Julie R ; LIVINGSTON, Robert B ; LINDEN, Hannah M ; ELLIS, Georgiana K ; SCHUBERT, Erin K ; DUNNWALD, Lisa K ; MANKOFF, David A</creatorcontrib><description>The response of bone-dominant (BD) breast cancer to therapy is difficult to assess by conventional imaging. Our preliminary studies have shown that quantitative serial 2-[(18)F] fluoro-2-deoxy-D: -glucose positron emission tomography (FDG PET) correlates with therapeutic response of BD breast cancer, but the relationship to long-term outcome measures is unknown. Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment.
We reviewed medical records of 405 consecutive breast cancer patients referred for FDG PET. Of these, 28 demonstrated metastatic BD breast cancer, were undergoing treatment, had at least 2 serial PET scans, and had abnormal FDG uptake on the first scan. Standardized uptake value (SUV) for the most conspicuous bone lesion at the initial scan, absolute change in SUV over an interval of 1-17 months, and percent change in SUV were considered as predictors of time-to-progression (TTP) and time to skeletal-related event (t-SRE).
Using proportional hazards regression, smaller percentage decreases in SUV (or increases in SUV) were associated with a shorter TTP (P < 0.006). A patient with no change in SUV was twice as likely to progress compared to a patient with a 42% median decrease in SUV. A higher SUV on the initial FDG PET predicted a shorter t-SRE (hazard ratio = 1.30, P < 0.02).
Changes in serial FDG PET may predict TTP in BD metastatic breast cancer patients. However, larger prospective trials are needed to validate changes in FDG PET as a surrogate endpoint for treatment response.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-006-9435-1</identifier><identifier>PMID: 17268819</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Adult ; Aged ; Anemias. Hemoglobinopathies ; Biological and medical sciences ; Bone and Bones - diagnostic imaging ; Bone and Bones - metabolism ; Bone and Bones - pathology ; Bone Neoplasms - diagnostic imaging ; Bone Neoplasms - pathology ; Bone Neoplasms - secondary ; Bones ; Breast cancer ; Breast Neoplasms - diagnostic imaging ; Breast Neoplasms - pathology ; Cancer research ; Cancer therapies ; Disease Progression ; Diseases of red blood cells ; Drug therapy ; Female ; Fluorodeoxyglucose F18 - pharmacology ; Glucose ; Gynecology. Andrology. Obstetrics ; Hematologic and hematopoietic diseases ; Humans ; Mammary gland diseases ; Medical sciences ; Medical treatment ; Middle Aged ; Neoplasm Metastasis ; Oncology ; Platelet diseases and coagulopathies ; Positron-Emission Tomography - methods ; Proportional Hazards Models ; Radiopharmaceuticals - pharmacology ; Retrospective Studies ; Tomography ; Tumors</subject><ispartof>Breast cancer research and treatment, 2007-09, Vol.105 (1), p.87-94</ispartof><rights>2007 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-adb2d652fbe07c94dc811066deec109b8c43fe242f960d6a47e0ae1eb17a2c403</citedby><cites>FETCH-LOGICAL-c453t-adb2d652fbe07c94dc811066deec109b8c43fe242f960d6a47e0ae1eb17a2c403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19029057$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17268819$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SPECHT, Jennifer M</creatorcontrib><creatorcontrib>TAM, Stephen L</creatorcontrib><creatorcontrib>KURLAND, Brenda F</creatorcontrib><creatorcontrib>GRALOW, Julie R</creatorcontrib><creatorcontrib>LIVINGSTON, Robert B</creatorcontrib><creatorcontrib>LINDEN, Hannah M</creatorcontrib><creatorcontrib>ELLIS, Georgiana K</creatorcontrib><creatorcontrib>SCHUBERT, Erin K</creatorcontrib><creatorcontrib>DUNNWALD, Lisa K</creatorcontrib><creatorcontrib>MANKOFF, David A</creatorcontrib><title>Serial 2-[18F] fluoro -2 -deoxy -D -glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><description>The response of bone-dominant (BD) breast cancer to therapy is difficult to assess by conventional imaging. Our preliminary studies have shown that quantitative serial 2-[(18)F] fluoro-2-deoxy-D: -glucose positron emission tomography (FDG PET) correlates with therapeutic response of BD breast cancer, but the relationship to long-term outcome measures is unknown. Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment.
We reviewed medical records of 405 consecutive breast cancer patients referred for FDG PET. Of these, 28 demonstrated metastatic BD breast cancer, were undergoing treatment, had at least 2 serial PET scans, and had abnormal FDG uptake on the first scan. Standardized uptake value (SUV) for the most conspicuous bone lesion at the initial scan, absolute change in SUV over an interval of 1-17 months, and percent change in SUV were considered as predictors of time-to-progression (TTP) and time to skeletal-related event (t-SRE).
Using proportional hazards regression, smaller percentage decreases in SUV (or increases in SUV) were associated with a shorter TTP (P < 0.006). A patient with no change in SUV was twice as likely to progress compared to a patient with a 42% median decrease in SUV. A higher SUV on the initial FDG PET predicted a shorter t-SRE (hazard ratio = 1.30, P < 0.02).
Changes in serial FDG PET may predict TTP in BD metastatic breast cancer patients. However, larger prospective trials are needed to validate changes in FDG PET as a surrogate endpoint for treatment response.</description><subject>Adult</subject><subject>Aged</subject><subject>Anemias. Hemoglobinopathies</subject><subject>Biological and medical sciences</subject><subject>Bone and Bones - diagnostic imaging</subject><subject>Bone and Bones - metabolism</subject><subject>Bone and Bones - pathology</subject><subject>Bone Neoplasms - diagnostic imaging</subject><subject>Bone Neoplasms - pathology</subject><subject>Bone Neoplasms - secondary</subject><subject>Bones</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnostic imaging</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Disease Progression</subject><subject>Diseases of red blood cells</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18 - pharmacology</subject><subject>Glucose</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Oncology</subject><subject>Platelet diseases and coagulopathies</subject><subject>Positron-Emission Tomography - methods</subject><subject>Proportional Hazards Models</subject><subject>Radiopharmaceuticals - pharmacology</subject><subject>Retrospective Studies</subject><subject>Tomography</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFktFqFDEUhgdR7Fp9AG8kCEp7ET3JZJLJpbTdKhQsuF6JhEzmTE2ZmaxJBtz38gHNugsFb7xKOHz5T06-VNVLBu8YgHqfGDRCUwBJtagbyh5VK9aomirO1ONqBUwqKluQJ9WzlO4BQCvQT6sTprhsW6ZX1e8vGL0dCaffWLv-ToZxCTEQygntMfzaEXpJ6N24uJCQbEPyOYaZ4ORT8mWTwxTuot3-2JGz9eU1vb3anJcimcLsc4gkR7R5wjmTMJAuzEj7MPnZlsKE2aZss3ekK1TKxNnZYSTbiL13OZHsJ9yHbWPpgYeGZ5vN7fnz6slgx4Qvjutp9XV9tbn4SG8-X3-6-HBDnWjqTG3f8V42fOgQlNOidy1jIGWP6BjornWiHpALPmgJvbRCIVhk2DFluRNQn1ZvD7nlBj8XTNmUuR2Oo50xLMnIlslat-y_IAeumuYv-Pof8D4scS5DGM64aJRoeYHYAXIxpBRxMNvoJxt3hoHZizcH8aaIN3vxZh_86hi8dBP2DyeOpgvw5gjY5Ow4xPLYPj1wGriG8nf-AD65tpg</recordid><startdate>20070901</startdate><enddate>20070901</enddate><creator>SPECHT, Jennifer M</creator><creator>TAM, Stephen L</creator><creator>KURLAND, Brenda F</creator><creator>GRALOW, Julie R</creator><creator>LIVINGSTON, Robert B</creator><creator>LINDEN, Hannah M</creator><creator>ELLIS, Georgiana K</creator><creator>SCHUBERT, Erin K</creator><creator>DUNNWALD, Lisa K</creator><creator>MANKOFF, David A</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20070901</creationdate><title>Serial 2-[18F] fluoro -2 -deoxy -D -glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)</title><author>SPECHT, Jennifer M ; TAM, Stephen L ; KURLAND, Brenda F ; GRALOW, Julie R ; LIVINGSTON, Robert B ; LINDEN, Hannah M ; ELLIS, Georgiana K ; SCHUBERT, Erin K ; DUNNWALD, Lisa K ; MANKOFF, David A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-adb2d652fbe07c94dc811066deec109b8c43fe242f960d6a47e0ae1eb17a2c403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anemias. Hemoglobinopathies</topic><topic>Biological and medical sciences</topic><topic>Bone and Bones - diagnostic imaging</topic><topic>Bone and Bones - metabolism</topic><topic>Bone and Bones - pathology</topic><topic>Bone Neoplasms - diagnostic imaging</topic><topic>Bone Neoplasms - pathology</topic><topic>Bone Neoplasms - secondary</topic><topic>Bones</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnostic imaging</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Disease Progression</topic><topic>Diseases of red blood cells</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18 - pharmacology</topic><topic>Glucose</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Oncology</topic><topic>Platelet diseases and coagulopathies</topic><topic>Positron-Emission Tomography - methods</topic><topic>Proportional Hazards Models</topic><topic>Radiopharmaceuticals - pharmacology</topic><topic>Retrospective Studies</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SPECHT, Jennifer M</creatorcontrib><creatorcontrib>TAM, Stephen L</creatorcontrib><creatorcontrib>KURLAND, Brenda F</creatorcontrib><creatorcontrib>GRALOW, Julie R</creatorcontrib><creatorcontrib>LIVINGSTON, Robert B</creatorcontrib><creatorcontrib>LINDEN, Hannah M</creatorcontrib><creatorcontrib>ELLIS, Georgiana K</creatorcontrib><creatorcontrib>SCHUBERT, Erin K</creatorcontrib><creatorcontrib>DUNNWALD, Lisa K</creatorcontrib><creatorcontrib>MANKOFF, David A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SPECHT, Jennifer M</au><au>TAM, Stephen L</au><au>KURLAND, Brenda F</au><au>GRALOW, Julie R</au><au>LIVINGSTON, Robert B</au><au>LINDEN, Hannah M</au><au>ELLIS, Georgiana K</au><au>SCHUBERT, Erin K</au><au>DUNNWALD, Lisa K</au><au>MANKOFF, David A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serial 2-[18F] fluoro -2 -deoxy -D -glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)</atitle><jtitle>Breast cancer research and treatment</jtitle><addtitle>Breast Cancer Res Treat</addtitle><date>2007-09-01</date><risdate>2007</risdate><volume>105</volume><issue>1</issue><spage>87</spage><epage>94</epage><pages>87-94</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>The response of bone-dominant (BD) breast cancer to therapy is difficult to assess by conventional imaging. Our preliminary studies have shown that quantitative serial 2-[(18)F] fluoro-2-deoxy-D: -glucose positron emission tomography (FDG PET) correlates with therapeutic response of BD breast cancer, but the relationship to long-term outcome measures is unknown. Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment.
We reviewed medical records of 405 consecutive breast cancer patients referred for FDG PET. Of these, 28 demonstrated metastatic BD breast cancer, were undergoing treatment, had at least 2 serial PET scans, and had abnormal FDG uptake on the first scan. Standardized uptake value (SUV) for the most conspicuous bone lesion at the initial scan, absolute change in SUV over an interval of 1-17 months, and percent change in SUV were considered as predictors of time-to-progression (TTP) and time to skeletal-related event (t-SRE).
Using proportional hazards regression, smaller percentage decreases in SUV (or increases in SUV) were associated with a shorter TTP (P < 0.006). A patient with no change in SUV was twice as likely to progress compared to a patient with a 42% median decrease in SUV. A higher SUV on the initial FDG PET predicted a shorter t-SRE (hazard ratio = 1.30, P < 0.02).
Changes in serial FDG PET may predict TTP in BD metastatic breast cancer patients. However, larger prospective trials are needed to validate changes in FDG PET as a surrogate endpoint for treatment response.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>17268819</pmid><doi>10.1007/s10549-006-9435-1</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2007-09, Vol.105 (1), p.87-94 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68163981 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Anemias. Hemoglobinopathies Biological and medical sciences Bone and Bones - diagnostic imaging Bone and Bones - metabolism Bone and Bones - pathology Bone Neoplasms - diagnostic imaging Bone Neoplasms - pathology Bone Neoplasms - secondary Bones Breast cancer Breast Neoplasms - diagnostic imaging Breast Neoplasms - pathology Cancer research Cancer therapies Disease Progression Diseases of red blood cells Drug therapy Female Fluorodeoxyglucose F18 - pharmacology Glucose Gynecology. Andrology. Obstetrics Hematologic and hematopoietic diseases Humans Mammary gland diseases Medical sciences Medical treatment Middle Aged Neoplasm Metastasis Oncology Platelet diseases and coagulopathies Positron-Emission Tomography - methods Proportional Hazards Models Radiopharmaceuticals - pharmacology Retrospective Studies Tomography Tumors |
| title | Serial 2-[18F] fluoro -2 -deoxy -D -glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T13%3A54%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serial%202-%5B18F%5D%20fluoro%20-2%20-deoxy%20-D%20-glucose%20positron%20emission%20tomography%20(FDG-PET)%20to%20monitor%20treatment%20of%20bone-dominant%20metastatic%20breast%20cancer%20predicts%20time%20to%20progression%20(TTP)&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=SPECHT,%20Jennifer%20M&rft.date=2007-09-01&rft.volume=105&rft.issue=1&rft.spage=87&rft.epage=94&rft.pages=87-94&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-006-9435-1&rft_dat=%3Cproquest_cross%3E1323079721%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212457482&rft_id=info:pmid/17268819&rfr_iscdi=true |